MEI Pharma licenses ME-401 to Kyowa Hakko Kirin in Japan

7 November 2018

The USA’s MEI Pharma (Nasdaq: MEIP) has announced the execution of a license agreement granting Japan’s Kyowa Hakko Kirin (TYO: 4151) exclusive rights to develop and commercialize ME-401 in Japan.

ME-401 is MEI's phosphatidylinositol 3-kinase (PI3K) delta inhibitor being developed by MEI for the treatment of patients with B-cell malignancies. MEI is planning to initiate a Phase II study to evaluate patients with follicular lymphoma that is intended to support an accelerated approval marketing application with the US Food and Drug Administration.

Financial terms of the collaboration

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK